Chronic opioid induced constipation in patients with nonmalignant pain: Challenges and opportunities

Therapeutic Advances in Gastroenterology

Volumn 8, Issue 4, 2015, Pages 206-220

  Nelson, Alfred D ^a   Camilleri, Michael ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

constipation; opioids; pain

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; AXELOPRAN; BISACODYL; DOCUSATE SODIUM PLUS SENNA EXTRACT; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MACROGOL; MAGNESIUM SALT; METHADONE; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALDEMEDINE; NALOXEGOL; NALOXONAZINE; NALOXONE; NALOXONE PLUS OXYCODONE; NARCOTIC ANALGESIC AGENT; OPIATE; OPIATE ANTAGONIST; PLACEBO; PRUCALOPRIDE; SENNA EXTRACT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ALGORITHM; ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CHRONIC CONSTIPATION; CHRONIC PAIN; CONSTIPATION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERANCE; DRUG WITHDRAWAL; FLATULENCE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERHIDROSIS; INCIDENCE; NAUSEA; NONHUMAN; NONMALIGNANT PAIN; OUTCOME ASSESSMENT; PAIN; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 84930440122     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X15578608     Document Type: Review

References (62)

1. Akbarali H. Inkisar A. Dewey W. (2014) Site and mechanism of morphine tolerance in the gastrointestinal tract. Neurogastroenterol Motil 26: 1361–1367.
2. Bell T. Panchal S. Miaskowski C. Bolge S. Milanova T. Williamson R. (2009) The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 10: 35–42.
3. Bryant A. Busby R. Bartolini W. Cordero E. Hannig G. Kessler M. (2010) Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 86: 760–765.
4. Burness C. (2014) Oxycodone / naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs 74: 353–375.
5. Camilleri M. Drossman D. Becker G. Webster L. Davies A. Mawe G. (2014) Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil 26: 1386–1395.
6. Camilleri M. Rothman M. Ho K. Etropolski M. (2011) Validation of a bowel function diary for assessing opioid-induced constipation. Am J Gastroenterol 106: 497–506.
7. Chey W. Webster L. Sostek M. Lappalainen J. Barker P. Tack J. (2014) Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 370: 2387–2396.
8. Chou R. Fanciullo G. Fine P. Adler J. Ballantyne J. Davies P. et al. (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10: 113–130.
9. Costa M. Brookes S. Hennig G. (2000) Anatomy and physiology of the enteric nervous system. Gut 47(Suppl. 4): iv15–iv19; discussion iv26.
10. Coyne K. Currie B. Holmes W. Crawley J. (2014 a) Assessment of a stool symptom screener and understanding the opioid-induced constipation symptom experience. Patient 18 September 2014. [Epub ahead of print].
11. Coyne K. Lo Casale R. Datto C. Sexton C. Yeomans K. Tack J. (2014 b) Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res 6: 269–281.
12. Cryer B. Katz S. Vallejo R. Popescu A. Ueno R. (2014) A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 15: 1825–1834.
13. Cuppoletti J. Chakrabarti J. Tewari K. Malinowska D. (2013) Methadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T 84 intestinal cells and recombinant human ClC-2, but not CFTR Cl- currents. Cell Biochem Biophys 66: 53–63.
14. Cuppoletti J. Chakrabarti J. Tewari K. Malinowska D. (2014) Differentiation between human ClC-2 and CFTR Cl- channels with pharmacological agents. Am J Physiol Cell Physiol 307: C479–C492.
15. de Maeyer J. Lefebvre R. Schuurkes J. (2008) 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 20: 99–112.
16. Duraffourd C. Kumala E. Anselmi L. Brecha N. Sternini C. (2014) Opioid-induced mitogen-activated protein kinase signaling in rat enteric neurons following chronic morphine treatment. PloS ONE 9: e110230.
17. Faassen F. (2003) Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharmaceut 263: 113–122.
18. Freedman M. Schwartz H. Roby R. Fleisher S. (1997) Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol 37: 904–907.
19. Gaertner J. Siemens W. Camilleri M. Davies A. Drossman D. Webster L. et al. (2015 Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol 49: 9–16.
20. Galligan J. Akbarali H. (2014) Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl 2: 17–21.
21. Hjalte F. Berggren A. Bergendahl H. Hjortsberg C. (2010) The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 40: 696–703.
22. Iyer S. Randazzo B. Tzanis E. Schulman S. Zhang H. Wang W. et al. (2011) Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health 14: 177–183.
23. Jadad A. Browman G. (1995) The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 274: 1870–1873.
24. Jamal M. Mareya S. Woldegeorgis F. Joswick T. Joswick R. (2012) Lubiprostone significantly improves treatment response in non-methadone opioid-induced bowel dysfunction patients with chronic, non-cancer pain: results from a phase 3, randomized, double-blind, placebo-controlled clinical trial. Gastroenterology 142: S144–S145.
25. Jansen J. Lorch D. Langan J. Lasko B. Hermanns K. Kleoudis C. et al. (2011) A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 12: 185–193.
26. Kalso E. Edwards J. Moore R. McQuay H. (2004) Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 112: 372–380.
27. Kang M. Maguma H. Smith T. Ross G. Dewey W. Akbarali H. (2012) The role of beta-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract. J Pharmacol Exp Ther 340: 567–576.
28. Koopmans G. Simpson K. de Andrés J. Lux E. Wagemans M. van Megen Y. (2014) Fixed ratio (2:1) prolonged-release oxycodone / naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives. Curr Med Res Opin 30: 2389–2396.
29. Kumar L. Barker C. Emmanuel A. (2013) Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract 2014: 141737.
30. Kurz A. Sessler D. (2003) Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63: 649–671.
31. Lembo A. Camilleri M. (2003) Chronic constipation. N Engl J Med 349: 1360–1368.
32. Leonard J. Baker D. (2015) Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Ann Pharmacother 49: 360–365.
33. Ling G. Paul D. Simantov R. Pasternak G. (1989) Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci 45: 1627–1636.
34. Liu M. Wittbrodt E. (2001) Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 23: 48–53.
35. Lowenstein O. Leyendecker P. Hopp M. Schutter U. Rogers P. Uhl R. et al. (2009) Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 10: 531–543.
36. Lowenstein O. Leyendecker P. Lux E. Blagden M. Simpson K. Hopp M. et al. (2010) Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate / severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 10: 12.
37. Meissner W. Schmidt U. Hartmann M. Kath R. Reinhart K. (2000) Oral naloxone reverses opioid-associated constipation. Pain 84: 105–109.
38. Michna E. Blonsky E. Schulman S. Tzanis E. Manley A. Zhang H. et al. (2011) Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 12: 554–562.
39. Mori T. Shibasaki Y. Matsumoto K. Shibasaki M. Hasegawa M. Wang E. et al. (2013) Mechanisms that underlie µ-opioid receptor agonist-induced constipation: differential involvement of µ-opioid receptor sites and responsible regions. J Pharmacol Exp Ther 347: 91–99.
40. Musial F. Enck P. Kalveram K. Erckenbrecht J. (1992) The effect of loperamide on anorectal function in normal healthy men. J Clin Gastroenterol 15: 321–324.
41. Neumann T. Paaschen H. Marcantonio A. Song D. Morisson P. Eldon M. (2007) Evaluation of single oral doses of NKTR-118 (PEG-NALOXEGOL) as a peripheral opioid antagonist (POA): a double-blind placebo-controlled study in healthy subjects. J Clin Pharmacol 47: 1210.
42. Ono H. Nakamura A. Matsumoto K. Horie S. Sakaguchi G. Kanemasa T. (2014) Circular muscle contraction in the mice rectum plays a key role in morphine-induced constipation. Neurogastroenterol Motil 26: 1396–1407.
43. Pappagallo M. (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182(Suppl. 5A): 11S–18S
44. Rentz A. Yu R. Muller-Lissner S. Leyendecker P. (2009) Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Medical Econ 12: 371–383.
45. Roberts M. Bentley M. Harris J. (2002) Chemistry for peptide and protein PEGylation. Adv Drug Delivery Rev 54: 459–476.
46. Ross G. Gabra B. Dewey W. Akbarali H. (2008) Morphine tolerance in the mouse ileum and colon. J Pharmacol Exp Ther 327: 561–572.
47. Russell J. Bass P. Goldberg L. Schuster C. Merz H. (1982) Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 78: 255–261.
48. Sandner-Kiesling A. Leyendecker P. Hopp M. Tarau L. Lejcko J. Meissner W. et al. (2010) Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 64: 763–774.
49. Shook J. Pelton J. Hruby V. Burks T. (1987) Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther 243: 492–500.
50. Sloots C. Rykx A. Cools M. Kerstens R. de Pauw M. (2010) Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 55: 2912–2921.
51. Sternini C. (2001) Receptors and transmission in the brain-gut axis: potential for novel therapies. III. Mu-opioid receptors in the enteric nervous system. Am J Physiol Gastrointest Liver Physiol 281: G8–15.
52. Sternini C. Patierno S. Selmer I. Kirchgessner A. (2004) The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 16(Suppl. 2): 3–16.
53. Sun W. Read N. Verlinden M. (1997) Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol 32: 34–38.
54. Sykes N. (1991) Oral naloxone in opioid-associated constipation. Lancet 337: 1475.
55. Tuteja A. Biskupiak J. Stoddard G. Lipman A. (2010) Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 22: 424–430.
56. Vickery R. Lebster L. Li Y. Schwertschlag U. Singla N. Canafax D. (2013) TD-1211 Phase 2b study demonstrates increased bowel movement frequency in patients with opioid-induced constipation regardless of baseline opioid dose. Pain 6: 11.11.
57. Vickery R. Li Y. Kohler R. Webster L. Singla N. Daniels O. (2011) TD-1211 demonstrates constipation-relieving effects, including decrease in rescue laxative use, in patients with opioid-induced constipation. Am J Gastroenterol 106(10 Suppl. 2): S513–S514.
58. Vondrackova D. Leyendecker P. Meissner W. Hopp M. Szombati I. Hermanns K. et al. (2008) Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 9: 1144–1154.
59. Webster L. Chey W. Tack J. Lappalainen J. Diva U. Sostek M. (2014) Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther 40: 771–779.
60. Webster L. Dhar S. Eldon M. Masuoka L. Lappalainen J. Sostek M. (2013) A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 154: 1542–1550.
61. Yuan C. (1996) Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 59: 469–475.
62. Yuan C. Foss J. (2000) Antagonism of gastrointestinal opioid effects. Reg Anesth Pain Med 25: 639–642.